The pinnacle of citations was achieved by a 2018 article on first-line atezolizumab plus chemotherapy in ES-SCLC; by March 2019, FDA conferred approval upon the PD-L1 inhibitor atezolizumab as a component of a first-line therapeutic regimen inclusive of etoposide and carboplatin, underscoring its unparalleled potential in the field, with additional trials presently underway. Here, CD274 is linked to small cell lung carcinoma.